For Healthcare Professionals

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma


About the study

The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  1. Histologically confirmed diagnosis of B-cell indolent Non-Hodgkin lymphoma with histological subtype limited to follicular lymphoma or marginal zone lymphoma, at initial diagnosis and without evidence of pathological transformation or clinical signs suggesting transformation
  2. At least 1 prior treatment with a CD20 antibody combination chemo-immunotherapy regimen
  3. Disease that has relapsed or was refractory after prior chemo-immunotherapy
  4. At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma 2007
  5. Eastern Cooperative Oncology Group performance status grade 0 or 1
  6. Laboratory values within protocol-defined parameters
  7. Agrees to protocol-defined use of effective contraception
  8. Men must agree not to donate sperm during and after the study for 6 months after the last dose of bendamustine, 12 months after the last dose of rituximab, or 3 months after the last dose of study medication, whichever is later
  9. Women of childbearing potential must have a negative serum or urine pregnancy test at Screening


  1. Prior treatment according to protocol-defined criteria
  2. Unable to receive background chemotherapy based on prior treatment history and cardiac function
  3. Known central nervous system lymphoma
  4. Diagnosed or treated for malignancy other than indolent Non-Hodgkin lymphoma
  5. History of stroke or intracranial hemorrhage within 6 months prior to randomization
  6. Requires anticoagulation with warfarin or equivalent Vitamin K antagonists
  7. Requires treatment with strong CYP3A inhibitors
  8. Clinically significant cardiovascular disease
  9. Known history of human immunodeficiency virus or active hepatitis C virus (HCV; ribonucleic acid [RNA] polymerase chain reaction [PCR]-positive) or active hepatitis B virus (HBV; DNA PCR-positive) infection or any uncontrolled active systemic infection requiring intravenous antibiotics
  10. Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
  11. Women who are pregnant or breastfeeding
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Email iconEmail Study Center

Study’s details






Phase 3

Participants needed


Est. Completion Date

May 2023

Treatment type



Janssen Research & Development, LLC identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.